Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
Merck
Cipla
Julphar
Colorcon

Generated: August 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,492,506

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,492,506
Title:Oligonucleotide chelate complex--polypeptide compositions and methods
Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.
Inventor(s): Bazinet; Michel (Montreal, CA), Vaillant; Andrew (Roxboro, CA)
Assignee: REPLICOR INC. (Montreal, CA)
Application Number:13/896,510
Patent Claims:1. A pharmaceutical composition comprising an oligonucleotide (ON) chelate complex, consisting of two or more ONs linked intermolecularly by a divalent cation, and at least one of: Thymosin .alpha.1; Any .alpha.-interferon or pegylated derivatives thereof; Any .beta.-interferon or pegylated derivatives thereof; Any .gamma.-interferon or pegylated derivatives thereof; Any .lamda.-interferon or pegylated derivatives thereof; Interferon .alpha.-2a or .alpha.-2b or .alpha.-N3; Interferon .beta.-1a or .beta.-1b; Interferon .gamma.-1b; Interferon .lamda.1 or .lamda.2 or .lamda.3; Pegylated interferon .alpha.-2a or .alpha.-2b or .lamda.1 or .lamda.2 or .lamda.3; Myrcludex B; Any antiviral cytokine or pegylated derivatives thereof; and Thymic protein A.

2. A pharmaceutical composition comprising an antiviral ON chelate complex, consisting of two or more antiviral ONs linked intermolecularly by a divalent cation, and at least one antiviral of: Thymosin .alpha.1; Any .alpha.-interferon or pegylated derivatives thereof; Any .beta.-interferon or pegylated derivatives thereof; Any .gamma.-interferon or pegylated derivatives thereof; Any .lamda.-interferon or pegylated derivatives thereof; Interferon .alpha.-2a or .alpha.-2b or .alpha.-N3; Interferon .beta.-1a or .beta.-1b; Interferon .gamma.-1b; Interferon .lamda.1 or .lamda.2 or .lamda.3; Pegylated interferon .alpha.-2a or .alpha.-2b or .lamda.1 or .lamda.2 or .lamda.3; Myrcludex B; Any antiviral cytokine or peqylated derivatives thereof; and Thymic protein A.

3. The pharmaceutical composition of claim 1 or 2, wherein said divalent metal cation is calcium.

4. The pharmaceutical composition of claim 1 or 2, wherein said divalent metal cation is magnesium.

5. The pharmaceutical composition of claim 1 or 2, wherein said divalent metal cation is iron (2+), manganese, copper or zinc.

6. The pharmaceutical composition of claim 1 or 2, wherein said divalent cation is comprised of two or more different divalent metal cations.

7. The pharmaceutical composition of claim 1 or 2, wherein said divalent cation is comprised of calcium and magnesium.

8. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one double stranded ON.

9. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON with at least one phosphorothioate linkage.

10. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one fully phosphorothioated ON.

11. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON with one 2' modified ribose.

12. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON which has each ribose 2' O-methylated.

13. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON comprising at least one 5'methylcytosine.

14. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON in which each cytosine is further 5'methylcytosine.

15. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON in which every ribose is 2' O-methylated and in which each cytosine is further 5'methylcytosine.

16. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises an oligonucleotide selected from SEQ ID NOs: 1-6 and 10-18.

17. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises an oligonucleotide selected from SEQ ID NOs: 7-9.

18. The pharmaceutical composition of claim 1 or 2, formulated for subcutaneous administration.

19. The pharmaceutical composition of claim 1 or 2, formulated for intravenous infusion.

20. The pharmaceutical composition of claim 1 or 2, formulated for at least one of the following routes of administration: aerosol inhalation, intraocular, oral ingestion, enteric, intramuscular injection, intraperitoneal injection, intrathecal injection, intrathecal infusion, intratracheal, intravenous injection and topically.

21. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON consisting of SEQ ID NO: 2.

22. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON consisting of SEQ ID NO: 11.

23. The pharmaceutical composition of claim 1 or 2, wherein said wherein said ON chelate complex comprises at least one ON consisting of SEQ ID NO: 18.

24. The pharmaceutical composition of claim 1 or 2, further comprising one or more of the following: entecavir, tenofovir disoproxil fumarate, telbuvidine, adefovir dipivoxil, lamivudine, ribavirin, telaprevir, boceprevir, GS-7977, tegobuvir, zanamivir, oseltamivir, ganciclovir, foscarnet, acyclovir, zidovudine, abacavir, lopinavir, ritonavir or efavirenz.

25. The pharmaceutical composition of claim 1 or 2, further comprising a carrier.

26. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated interferon .alpha.-2a.

27. A pharmaceutical composition comprising an ON chelate complex consisting of two or more ONs linked intermolecularly by a divalent cation, comprising at least one oligonucleotide consisting of SEQ ID NO: 18, and pegylated interferon .alpha.-2a.

28. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated interferon .alpha.-2a.

29. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and thymosin .alpha.1.

30. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and thymosin .alpha.1.

31. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and thymosin .alpha.1.

32. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 2, and interferon .alpha.-2b.

33. A pharmaceutical composition comprising an ON chelate complex consisting of two or more ONs linked intermolecularly by a divalent cation, comprising at least one oligonucleotide consisting of SEQ ID NO: 18, and interferon .alpha.-2b.

34. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and interferon .alpha.-2b.

35. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated thymosin .alpha.1.

36. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and pegylated thymosin .alpha.1.

37. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated thymosin .alpha.1.

38. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated interferon .alpha.-2b.

39. A pharmaceutical composition comprising an ON chelate complex consisting of two or more ONs linked intermolecularly by a divalent cation, comprising an oligonucleotide consisting of SEQ ID NO: 18, and pegylated interferon .alpha.-2b.

40. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated interferon .alpha.-2b.

41. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and interferon .lamda.1.

42. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and interferon .lamda.1.

43. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and interferon .lamda.1.

44. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated interferon .lamda.1.

45. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and pegylated interferon .lamda.1.

46. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated interferon .lamda.1.

Details for Patent 9,492,506

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Try a Free Trial REPLICOR INC. (Montreal, CA) 2032-05-18 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Try a Free Trial REPLICOR INC. (Montreal, CA) 2032-05-18 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Try a Free Trial REPLICOR INC. (Montreal, CA) 2032-05-18 RX search
Vidara Therapeutics Research Ltd ACTIMMUNE interferon gamma-1b VIAL; SINGLE-USE 103836 001 1999-02-25   Try a Free Trial REPLICOR INC. (Montreal, CA) 2032-05-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Covington
Cantor Fitzgerald
Express Scripts
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.